María Nieto Cid

María Nieto Cid

Auto-generated profile, based on publicly available information

María Nieto Cid

Service of Allergy, University Hospital La Plana, 12540 Villarreal, Spain

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 February 2022 in Heart & Lung
Verified
Journal Article
Closed access
DED. El-Qutob
D. El-Qutob
LAL. Alvarez-Arroyo
L. Alvarez-Arroyo
IBI. Barreda
I. Barreda
MNM. Nieto
M. Nieto
MPM. Pin
M. Pin
FCF.J. Carrera-Hueso
F.J. Carrera-Hueso

8 April 2023 in Pediatric Allergy and Immunology
Verified
Journal Article
Closed access
MNMaría Nieto‐Cid
María Nieto‐Cid
TGTeresa Garriga-Baraut
Teresa Garriga-Baraut
APAna Mª. Plaza‐Martín
Ana Mª. Plaza‐Martín
MTMiguel Tortajada-Girbés
Miguel Tortajada-Girbés
JTJavier Torres-Borrego
Javier Torres-Borrego
ANAntonio Nieto‐García
Antonio Nieto‐García

30 January 2024
Verified
Journal Article
Open access
PDF file
AMAngel Mazon
Angel Mazon
DJDah-Tay Jang
Dah-Tay Jang
BFBegoña Ferrer
Begoña Ferrer
SUSonia Uixera
Sonia Uixera
MPMaria Perez-Sabido
Maria Perez-Sabido
ANAntonio Nieto
Antonio Nieto
Desensitization (DSZ) or oral tolerance induction is increasingly used in children who do not outgrow their food allergies. Off-label omalizumab (OMZ) is used as adjuvant therapy for those with seve

28 November 2023
Verified
Journal Article
Open access
PDF file
JMJaume Martí-Garrido
Jaume Martí-Garrido
JKJon R Konradsen
Jon R Konradsen
GHGunilla Hedlin
Gunilla Hedlin
MHMarianne van Hage
Marianne van Hage
AGAntonio Nieto García
Antonio Nieto García
AMAngel Mazon
Angel Mazon
Aim: Asthma affects millions of people worldwide and generates a considerable economic impact. This study aims to compare the specific immunoglobulin E (sIgE) profile in sensitized children with

1 June 2022 in Reumatología Clínica
Verified
Journal Article
Open access
MRMontserrat Robustillo-Villarino
Montserrat Robustillo-Villarino
LÁLaura Álvarez-Arroyo
Laura Álvarez-Arroyo
FCFrancisco Javier Carrera-Hueso
Francisco Javier Carrera-Hueso
IBInés Barreda-Altaba
Inés Barreda-Altaba
MNMaría Nieto-Cid
María Nieto-Cid
DEDavid El-Qutob
David El-Qutob
Fundamentos: Las enfermedades inflamatorias inmunomediadas (IMID) predisponen a un aumento del riesgo infeccioso al modificar la respuesta inmune del huésped, que resulta crucial para la resolución de la infección por SARS-CoV-2. Las últimas publicaciones indican que los pacientes con IMID y sus tratamientos de base no empeoran el pronóstico de la infección por SARS-CoV-2.